Bayer acquires Icon Genetics AG

March 2006
Chemical Business;Mar2006, Vol. 20 Issue 3, p76
Trade Publication
Reports on the acquisition of Icon Genetics AG, a biotechnology company in Munich, Germany, by Bayer Innovation GmbH, a subsidiary of the Bayer Group, in Düsseldorf. Involvement of Icon Genetics in the development processes for the biotechnological production of biopharmaceuticals and other products in plants; Total number of patents granted or applied for by Icon Genetics; Information on Bayer Innovation.


Related Articles

  • Bayer buys German biotech co Icon Genetics.  // Chemical Business;Feb2006, Vol. 20 Issue 2, p84 

    Reports on the acquisition of biotechnology company Icon Genetics AG by chemical company Bayer Innovation GmbH in Munich, Germany in February 2006. Information on Icon Genetics; Significance of the acquisition to Bayer.

  • Bayer targets production of pharmaceuticals on tobacco plants.  // Process Engineering;Nov/Dec2006, Vol. 87 Issue 8, p44 

    The article reports on the intention of Icon Genetics AG, a subsidiary of Bayer Innovation GmbH, on the production of pharmaceuticals from tobacco plants employing its MagniCON process. According to group officials at a press conference, Bayer Innovation GmbH considered that said process was the...

  • New Investments Revive Hopes for Plant-Made Pharmaceuticals.  // BioPharm International;Nov2008, Vol. 21 Issue 11, p12 

    The article reports that Medicago Inc. and Bayer Innovation GmbH are reviving hopes for plant-made pharmaceuticals in the U.S. On September 23, 2008, Medicago announced that Philip Morris International Inc. invested $16 million to fund the development of pandemic and seasonal influenza vaccines...

  • XTL BIOPHARMACEUTICALS TO ACQUIRE MINOGUARD LTD.  // Biotech Financial Reports;Apr2011, Vol. 18 Issue 4, p7 

    The article announces the acquisition of drug manufacturer MinoGuard Ltd. by XTL Biopharmaceuticals Ltd. It reports that the latter has obtained exclusive license to use the former's technology in return for royalties on sales in the clinical development. It sates that MinoGuard's leading drug,...

  • Bristol-Myers Squibb Completes Acquisition of Amylin Pharmaceuticals Inc.  // Biomedical Market Newsletter;8/15/2012, Vol. 21, p1 

    The article presents information on the acquisition of Amylin Pharmaceuticals Inc. by Bristol-Myers Squibb Co. Bristol-Myers Squibb acquired all of the outstanding shares of Amylin common stock. Bristol-Myers Squibb is a global biopharmaceutical company focused on the development, discovery and...

  • 2016: A Biopharma Market in Flux. LOONEY, WILLIAM // Pharmaceutical Executive;Jan2016, Vol. 36 Issue 1, p3 

    The author offers developments in the biopharmaceutics industry in 2016. He indicates that 2015 ranks second only to the 1996 of novel U.S. Food and Drug Administration (FDA) approval, the initiative of the multinational company Google Inc. to use data strength to carve a broader role in drug...

  • REPORTERS Notebook.  // Drug Store News;10/20/2008, Vol. 30 Issue 13, p21 

    The article offers news briefs related to the pharmaceutical biotechnology industry in the U.S. The flu medication Tamiflu was cited as significant second line of defense against flu by the U.S. Centers for Disease Control and Prevention. Link Medicine has raised $40 million to finance clinical...

  • USING PATENT CITATION ANALYSIS TO TARGET/VALUE M& A CANDIDATES. Breitzman, Anthony; Thomas, Patrick // Research Technology Management;Sep/Oct2002, Vol. 45 Issue 5, p28 

    Discusses how the analysis of company patent portfolios can aid the evaluation of mergers and acquisitions (M&A). Concept of patent citation analysis; Ways in which patent analysis can be used for M&A evaluation; Applications of patent analysis.

  • US Oncology Is Set to Be Acquired by Mckesson.  // Chain Drug Review;11/22/2010, Vol. 32 Issue 20, p55 

    The article offers updates related to health care services in the U.S. including the acquisition of US Oncology Inc. by McKesson Corp., the plan of the country's Food and Drug Administration (FDA) to develop methods that could assess new drug products and the revelation of New York eHealth...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics